ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TRX Tissue Regenix Group Plc

57.50
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00BNTXR104 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 57.50 56.00 59.00 57.50 57.50 57.50 554 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 29.49M -302k -0.0043 -133.72 40.58M
Tissue Regenix Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 57.50p. Over the last year, Tissue Regenix shares have traded in a share price range of 50.50p to 74.00p.

Tissue Regenix currently has 70,574,468 shares in issue. The market capitalisation of Tissue Regenix is £40.58 million. Tissue Regenix has a price to earnings ratio (PE ratio) of -133.72.

Tissue Regenix Share Discussion Threads

Showing 13326 to 13350 of 14850 messages
Chat Pages: Latest  534  533  532  531  530  529  528  527  526  525  524  523  Older
DateSubjectAuthorDiscuss
05/3/2021
12:23
The trades at .678p are buys - I just topped up at .6778p
channel pirate
05/3/2021
12:07
Who knows. The share price action this morning isn't particularly encouraging...
cyberbub
05/3/2021
08:40
cyberbub >> You think the overhang has gone now?
topnotch
04/3/2021
14:40
Massive 60M trade gone through, almost 1% of the company. I suspect it must be a sell worked over a few days. Let's see if we get a reversal now??
cyberbub
03/3/2021
11:51
Looks like the trend lines are being followed almost perfectly since late Dec and I did expect this to touch 0.7p (mid) so hoping we have a solid bounce from here!
topnotch
02/3/2021
12:07
SP closed bang on the 20 SMA. Let's see if we find support again around these levels, touch wood....
cyberbub
26/2/2021
07:31
Having Glenn as permanent chairman makes sense to me. I was impressed by him at CSRT.
cerrito
25/2/2021
11:56
Chart suggesting next breather .9p
red army
25/2/2021
09:29
Looking good for a rise up today
monster500
24/2/2021
18:27
Nice close. Let's see if volume picks up in the coming days. Would be good to see a run towards 1p, I don't think that would be expensive given the prospects and IP here.NAI
cyberbub
24/2/2021
14:31
Nice share price action so far
cyberbub
24/2/2021
13:21
Bit quiet on here?
cyberbub
19/2/2021
16:56
They've trimmed a little after the big rise. No big deal IMO.
cyberbub
19/2/2021
16:46
new TR1 out, Lombard Odier Asset Management
ultrasilva
19/2/2021
11:31
The important thing is that the chart is still in play.
red army
19/2/2021
11:22
Not clear why it fell so far yesterday..... seemed it was falling on quite low volume.
emeraldzebra
19/2/2021
10:39
Not one to sell, the growth hasn’t even started yet, keen buyers on the mini dips after a few got subtly mugged!

I added a few more, along with KNB,MXC,NEX & PPS all on pull backs.

ny boy
19/2/2021
10:30
@Minja19 thank you. please define considerable :)
ultrasilva
19/2/2021
10:17
Nice to have a chartist giving us some accurate information - Thank You Minja19
channel pirate
19/2/2021
10:05
Now due a considerable pop up
minja19
19/2/2021
09:03
Pinged off the 8 ema at open
Tick up coming
Fingers xxd

minja19
18/2/2021
23:07
New article on proactive investors.

Tissue Regenix ready to build on strong performance through pandemic
Philip Whiterow
14:10 Thu 18 Feb 2021

ultrasilva
18/2/2021
20:06
FYI

Smith & Nephew revenues and profit dropped quite a lot in 2020 - because of elective surgeries postponed. TRX revenues have not...



In 2020 we continued to strengthen Smith & Nephew through increased investment in R&D, new product launches and strategic acquisitions in our higher-growth segments. We achieved this while also managing unprecedented disruption from COVID-19. The resilience of the business and strength of the balance sheet also meant we are able to maintain our progressive dividend policy,” said Roland Diggelmann, chief executive of Smith & Nephew.

"We start 2021 with three clear priorities: to return to top-line growth and recapture momentum; to drive further operational improvement, and to continue to respond effectively to COVID-19. We will build on the progress we are starting to make in areas where we have recently invested and introduced innovation. We will again invest more in R&D and I am excited by the pipeline of new technologies approaching launch, and by the potential of our recent acquisitions,” he added.

ultrasilva
18/2/2021
17:35
Someone was suggesting a gap at 0.75p?
cyberbub
18/2/2021
17:19
Which one?
dogwalker
Chat Pages: Latest  534  533  532  531  530  529  528  527  526  525  524  523  Older